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1. INTRODUCTION {#jcmm14836-sec-0001}
===============

Neuroblastoma (NB) is the most common solid tumour outside of the cranium in children, especially within the first 5 years after birth (median age of diagnosis at about 17 months).[1](#jcmm14836-bib-0001){ref-type="ref"}, [2](#jcmm14836-bib-0002){ref-type="ref"}, [3](#jcmm14836-bib-0003){ref-type="ref"} The tumours are most common in the abdomen (65%), followed by the neck, pelvis and chest (2). Neuroblastoma is a neuroendocrine tumour, which originates from the developing sympathetic nervous system, and its prevalence varies worldwide, affecting approximately 8‐14 individuals per million in the developed countries.[4](#jcmm14836-bib-0004){ref-type="ref"}

Possible risk factors suspected of aiding the development of NB in children include parental exposure to radiation sources, solders, wood dust and hydrocarbons.[5](#jcmm14836-bib-0005){ref-type="ref"}, [6](#jcmm14836-bib-0006){ref-type="ref"} Hence, degradation of environment may contribute to the occurrence of the cancer. Furthermore, with the advances in regenerative medicine and the use of novel biomaterials in implants such risks may increase.[7](#jcmm14836-bib-0007){ref-type="ref"}, [8](#jcmm14836-bib-0008){ref-type="ref"}

Our group performed in the past years several meta‐analyses,[9](#jcmm14836-bib-0009){ref-type="ref"}, [10](#jcmm14836-bib-0010){ref-type="ref"}, [11](#jcmm14836-bib-0011){ref-type="ref"} which underlined the role of polymorphisms in various cancer‐associated genes. Over the last decade, genome‐wide association studies (GWAS) have identified several loci linked to NB susceptibility,[12](#jcmm14836-bib-0012){ref-type="ref"}, [13](#jcmm14836-bib-0013){ref-type="ref"}, [14](#jcmm14836-bib-0014){ref-type="ref"}, [15](#jcmm14836-bib-0015){ref-type="ref"}, [16](#jcmm14836-bib-0016){ref-type="ref"}, [17](#jcmm14836-bib-0017){ref-type="ref"}, [18](#jcmm14836-bib-0018){ref-type="ref"}, [19](#jcmm14836-bib-0019){ref-type="ref"}, [20](#jcmm14836-bib-0020){ref-type="ref"}, [21](#jcmm14836-bib-0021){ref-type="ref"}, [22](#jcmm14836-bib-0022){ref-type="ref"} of which the LIM domain only 1 (LMO1) gene at 11p15.4 represents a promising candidate.[14](#jcmm14836-bib-0014){ref-type="ref"} LMO1 was recognized as neuroblastoma oncogene.[14](#jcmm14836-bib-0014){ref-type="ref"} It also acts as an oncogene in colorectal cancer (CRC) and lung cancer. LMO1 overexpression is a new predictive marker for anti‐EGFR therapy.[23](#jcmm14836-bib-0023){ref-type="ref"}, [24](#jcmm14836-bib-0024){ref-type="ref"} However, no significant differences were observed for LMO1 gene expression level between tumour tissues and corresponding adjacent benign tissues in human breast cancer, hepatocellular carcinoma (HCC) and gastric cancer (GC), which suggests that LMO1 gene may display a more complex functional network in these cancers.[24](#jcmm14836-bib-0024){ref-type="ref"} Sun et al[25](#jcmm14836-bib-0025){ref-type="ref"} have found that the expression levels of LMO1 in gastric cancer tissues were higher than those in adjacent tissues and the overexpression of LMO1 could be as a markers of poor prognosis. Deregulated expression of LMO1 may be involved in the development and maintenance of T‐ALL (T‐acute lymphoblastic leukaemia).[26](#jcmm14836-bib-0026){ref-type="ref"}

Thus far, several studies have investigated LMO1 polymorphisms and their impact on NB susceptibility, with varying and inconclusive results.[14](#jcmm14836-bib-0014){ref-type="ref"}, [20](#jcmm14836-bib-0020){ref-type="ref"}, [27](#jcmm14836-bib-0027){ref-type="ref"}, [28](#jcmm14836-bib-0028){ref-type="ref"}, [29](#jcmm14836-bib-0029){ref-type="ref"}, [30](#jcmm14836-bib-0030){ref-type="ref"}, [31](#jcmm14836-bib-0031){ref-type="ref"}, [32](#jcmm14836-bib-0032){ref-type="ref"}, [33](#jcmm14836-bib-0033){ref-type="ref"} In the current study, we performed an up‐to‐date meta‐analysis to more precisely evaluate the association between specific LMO1 polymorphisms and NB susceptibility.

2. METHODS {#jcmm14836-sec-0002}
==========

2.1. Literature search {#jcmm14836-sec-0003}
----------------------

To identify all potentially eligible literature, PubMed, Scopus and Web of Science databases were searched for relevant publications up to February 2019. The search keywords were 'neuroblastoma' and 'LIM domain only 1 or LMO1' and 'polymorphism or mutation or variation'. Studies were included in our meta‐analysis if they met the following inclusion criteria: (a) original case‐control studies; and (b) studies comprising necessary genotyping data of LMO1 polymorphisms in both disease cases and controls. The exclusion criteria were as follows: (a) case reports, conference abstracts, meta‐analyses and duplication data; and (b) studies lacking genotype information.

2.2. Data extraction {#jcmm14836-sec-0004}
--------------------

Two investigators independently searched literature and extracted the appropriate data from eligible studies. Data collected from each study included: the first author, publication date, country, ethnicity of study participants, control‐population source, genotyping methods of LOM1 polymorphisms, genotype distributions in cases and controls, and the result of the HWE test (Table [1](#jcmm14836-tbl-0001){ref-type="table"}).

###### 

Characteristics of all studies included in the meta‐analysis

  First author   Year   Country   Ethnicity             Source of control   Genotyping method       Case/Control   Cases   Controls   HWE (P)                                                    
  -------------- ------ --------- --------------------- ------------------- ----------------------- -------------- ------- ---------- --------- ------ ------ ------ ------ ------ ------ ------ -------
  rs110419                                                                                                         AA      AG         GG        A      G      AA     AG     GG     A      G       
  Capasso M      2013   Italy     Caucasian             PB                  Illumina HumanHap550    323/774        87      152        84        326    320    133    370    271    636    912    0.727
  Capasso M      2013   USA       European American     PB                  Illumina HumanHap550    1626/2575      509     787        330       1805   1447   599    1310   666    2508   2642   0.357
  He J           2016   China     Asian                 HB                  TaqMan                  256/531        103     117        36        323    189    159    275    97     593    469    0.248
  He L           2018   China     Asian                 HB                  TaqMan                  313/762        150     118        45        418    208    279    355    128    913    611    0.405
  Latorre V      2012   USA       African American      HB                  Illumina HumanHap 550   365/2491       223     124        18        570    160    1491   863    137    3845   1137   0.409
  Lu J           2015   China     Asian                 HB                  MassARRAY iPLEX         244/305        --      --         --        359    129    --     --     --     369    241    --
  Oldridge DA    2015   USA       European American     N.A                 Illumina HumanHap550    2101/4202      --      --         --        2349   1853   --     --     --     4110   4294   --
  Wang K         2011   USA       Discovery             N.A                 Illumina HumanHap550    1627/3254      --      --         --        1790   1464   --     --     --     3189   3319   --
  Wang K         2011   USA       US replication        N.A                 Illumina Human610       190/1507       --      --         --        232    148    --     --     --     1477   1537   --
  Wang K         2011   USA       UK replication        N.A                 TaqMan                  253/845        --      --         --        268    238    --     --     --     811    879    --
  Wang K         2011   USA       Italian replication   N.A                 TaqMan                  181/491        --      --         --        177    185    --     --     --     403    579    --
  Zhang J        2017   China     Asian                 HB                  TaqMan                  374/812        150     171        53        471    277    245    417    150    907    717    0.239
  rs4758051                                                                                                        GG      AG         AA        G      A      GG     AG     AA     G      A       
  Capasso M      2013   Italy     Caucasian             PB                  Illumina HumanHap550    340/792        70      156        114       296    384    141    405    246    687    897    0.248
  Capasso M      2013   USA       European American     PB                  Illumina HumanHap550    1624/2571      436     787        401       1659   1589   525    1292   754    2342   2800   0.507
  He J           2016   China     Asian                 HB                  TaqMan                  256/531        95      126        35        316    196    194    242    95     630    432    0.199
  He L           2018   China     Asian                 HB                  TaqMan                  313/762        138     123        52        399    227    256    364    142    876    648    0.530
  Latorre V      2012   USA       African American      HB                  Illumina HumanHap 550   365/2491       239     108        18        586    144    1692   713    86     4097   885    0.310
  Lu J           2015   China     Asian                 HB                  MassARRAY iPLEX         244/305        --      --         --        332    156    --     --     --     357    253    --
  Oldridge DA    2015   USA       European American     N.A                 Illumina HumanHap550    2101/4202      --      --         --        2059   2143   --     --     --     4605   3799   --
  Wang K         2011   USA       Discovery             N.A                 Illumina HumanHap550    1627/3254      --      --         --        1660   1594   --     --     --     2929   3579   --
  Wang K         2011   USA       US replication        N.A                 Illumina Human610       190/1507       --      --         --        209    171    --     --     --     1356   1658   --
  Wang K         2011   USA       UK replication        N.A                 TaqMan                  253/845        --      --         --        258    248    --     --     --     761    930    --
  Wang K         2011   USA       Italian replication   N.A                 TaqMan                  181/491        --      --         --        163    199    --     --     --     412    570    --
  Zhang J        2017   China     Asian                 HB                  TaqMan                  374/812        145     185        44        475    273    282    380    150    944    680    0.271
  rs10840002                                                                                                       AA      AG         GG        A      G      AA     AG     GG     A      G       
  He J           2016   China     Asian                 HB                  TaqMan                  256/531        90      124        42        304    208    182    240    109    604    458    0.070
  He L           2018   China     Asian                 HB                  TaqMan                  313/762        120     128        65        368    258    240    375    147    855    669    0.981
  Latorre V      2012   USA       African American      HB                  Illumina HumanHap 550   365/2491       204     128        33        536    194    1430   897    164    3757   1225   0.148
  Lu J           2015   China     Asian                 HB                  MassARRAY iPLEX         244/305        --      --         --        317    171    --     --     --     342    268    --
  Wang K         2011   USA       Discovery             N.A                 Illumina HumanHap550    1627/3254      --      --         --        1367   1887   --     --     --     2408   4100   --
  Wang K         2011   USA       US replication        N.A                 Illumina Human610       190/1507       --      --         --        167    213    --     --     --     1145   1869   --
  Wang K         2011   USA       UK replication        N.A                 TaqMan                  253/845        --      --         --        187    319    --     --     --     608    1082   --
  Zhang J        2017   China     Asian                 HB                  TaqMan                  374/812        132     186        56        450    298    260    384    168    904    720    0.233
  rs204938                                                                                                         AA      AG         GG        A      G      AA     AG     GG     A      G       
  He J           2016   China     Asian                 HB                  TaqMan                  256/531        164     83         9         411    101    354    165    12     873    189    0.153
  He L           2018   China     Asian                 HB                  TaqMan                  313/762        200     97         16        497    129    476    258    28     1210   314    0.336
  Latorre V      2012   USA       African American      HB                  Illumina HumanHap 550   365/2490       42      162        161       246    484    241    1040   1209   1522   3458   0.426
  Lu J           2015   China     Asian                 HB                  MassARRAY iPLEX         244/305        --      --         --        359    129    --     --     --     489    121    --
  Wang K         2011   USA       Discovery             N.A                 Illumina HumanHap550    1627/3254      --      --         --        1660   1594   --     --     --     3644   2864   --
  Wang K         2011   USA       US replication        N.A                 Illumina Human610       190/1507       --      --         --        190    190    --     --     --     1658   1356   --
  Wang K         2011   USA       UK replication        N.A                 TaqMan                  253/845        --      --         --        253    253    --     --     --     946    744    --
  Zhang J        2017   China     Asian                 HB                  TaqMan                  374/812        241     119        14        601    147    522    262    28     1306   318    0.485
  rs2168101                                                                                                        GG      GT         TT        G      T      GG     GT     TT     G      T       
  He J           2018   China     Asian                 HB                  TaqMan                  373/812        245     117        11        607    139    407    342    63     1156   468    0.448
  He L           2018   China     Asian                 HB                  TaqMan                  313/762        214     85         14        513    113    401    310    51     1112   412    0.389
  Oldridge DA    2015   USA       European American     N.A                 Illumina HumanHap550    --             --      --         --        3185   1017   --     --     --     5774   2630   --
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2.3. Statistical analysis {#jcmm14836-sec-0005}
-------------------------

All analyses were performed using STATA 14.1 (Stata Corporation). Departure from Hardy‐Weinberg equilibrium (HWE) in controls was examined by the *χ* ^2^ test. The strength of the association between LMO1 polymorphisms and NB risk was assessed by pooled odds ratios (ORs) and their 95% confidence intervals (CIs). The *Z*‐test was implemented to establish the statistical significance of the pooled ORs. We estimated the between‐study heterogeneity by the *Q*‐test and *I* ^2^‐test, with *P* \< .10 indicating the presence of heterogeneity. In case of heterogeneity, a random‐effect model was used; otherwise, a fixed‐effect model was employed.

We determined publication bias using funnel plots for visual inspection and by conducting quantitative estimations using the Egger\'s test. Sensitivity analyses were carried out by sequentially ignoring a single study at a time to assess the impact of individual data sets on the pooled ORs.

3. RESULTS {#jcmm14836-sec-0006}
==========

3.1. Study characteristics {#jcmm14836-sec-0007}
--------------------------

Figure [1](#jcmm14836-fig-0001){ref-type="fig"}A shows a flow chart of the study selection procedure. Ultimately, 9 published articles[14](#jcmm14836-bib-0014){ref-type="ref"}, [20](#jcmm14836-bib-0020){ref-type="ref"}, [27](#jcmm14836-bib-0027){ref-type="ref"}, [28](#jcmm14836-bib-0028){ref-type="ref"}, [29](#jcmm14836-bib-0029){ref-type="ref"}, [30](#jcmm14836-bib-0030){ref-type="ref"}, [31](#jcmm14836-bib-0031){ref-type="ref"}, [32](#jcmm14836-bib-0032){ref-type="ref"}, [33](#jcmm14836-bib-0033){ref-type="ref"} that met our inclusion criteria were identified: 12 case‐control studies on rs110419 and rs4758051 polymorphisms, 8 studies on rs10840002 and rs204938 polymorphisms, and three studies on the rs2168101polymorphism were also included in our meta‐analysis. The Figure [1](#jcmm14836-fig-0001){ref-type="fig"}B‐D illustrates the position of the analysed polymorphisms within the LMO1 gene. The articles were published between 2011 and 2018, and they include representatives of major ethnic groups (Caucasians, European Americans, African Americans and Asians). The main characteristics of these studies are listed in Table [1](#jcmm14836-tbl-0001){ref-type="table"}.

![Basic information about the presented study. (A) Flow chart of the study selection procedure, (B) map of the human LMO1 gene (USCS genome browser: chr11:8,224,449‐8,263,388). Exons 1‐4 are numbered and represented by black boxes. C) Positions of the single‐nucleotid variations within the first intron of the LMO1 gene (D) positions of the single‐nucleotid variations within the 3′ UTR region of the LMO1 gene (not up to scale)](JCMM-24-1160-g001){#jcmm14836-fig-0001}

### 3.1.1. Association of rs110419 polymorphism and neuroblastoma risk {#jcmm14836-sec-0008}

Quantitative analysis revealed that the rs110419 variant markedly decreased the risk of NB in heterozygous (OR = 0.72, 95%CI = 0.65‐0.79, *P* \< .00001, AG vs AA), homozygous (OR = 0.59, 95%CI = 0.52‐0.67, *P* \< .00001, GG vs AA), dominant, (OR = 0.68, 95%CI = 0.59‐0.78, *P* \< .00001, AG + GG vs AA), recessive (OR = 0.73, 95%CI = 0.66‐0.82, *P* \< .00001, GG vs AG + AA) and allele (OR = 0.75, 95%CI = 0.71‐0.79, *P* \< .00001, G vs A) genetic models (Table [2](#jcmm14836-tbl-0002){ref-type="table"}, Figure [2](#jcmm14836-fig-0002){ref-type="fig"}).

###### 

Association between LMO1 polymorphisms and susceptibility to neuroblastoma

  Polymorphism   No.             Genetic model      Test of association   Heterogeneity (*I* ^2^ (%), *P*)   Egger\'s test                             
  -------------- --------------- ------------------ --------------------- ---------------------------------- --------------- ------- ---------- ------ ------
  rs110419       6               AG vs AA           0.72 (0.65‐0.79)      6.77                               \<.00001        8.15    39         .15    .643
  6              GG vs AA        0.59 (0.52‐0.67)   8.09                  \<.00001                           4.03            0       .55        .565   
  6              AG + GG vs AA   0.68 (0.59‐0.78)   5.29                  \<.00001                           10.65           53      .06        .772   
  6              GG vs AG + AA   0.73 (0.66‐0.82)   5.51                  \<.00001                           1.66            0       .89        .411   
  12             G vs A          0.75 (0.71‐0.79)   10.14                 \<.00001                           17.78           38      .09        .293   
  rs4758051      6               AG vs GG           0.85 (0.71‐1.01)      1.85                               .06             13.56   63         .02    .487
  6              AA vs GG        0.76 (0.61‐0.96)   2.32                  .02                                12.36           60      .03        .207   
  6              AG + AA vs GG   0.83 (0.70‐0.99)   2.08                  .04                                15.62           68      .008       .363   
  6              AA vs AG + GG   0.86 (0.70‐1.06)   1.38                  .17                                13.51           63      .02        .612   
  12             A vs G          0.86 (0.75‐0.99)   2.13                  .03                                121.1           91      \<.00001   .245   
  rs10840002     4               AG vs AA           0.92 (0.80‐1.05)      1.24                               .22             9.98    40         .17    .764
  4              GG vs AA        0.89 (0.65‐1.23)   0.71                  .48                                8.04            63      .05        .750   
  4              AG + GG vs AA   0.91 (0.80‐1.04)   1.35                  .18                                4.38            32      .22        .506   
  4              GG vs AG + AA   0.94 (0.68‐1.30)   0.37                  .71                                9.98            70      .02        .724   
  8              G vs A          0.87 (0.79‐0.95)   3.00                  .003                               15.31           54      .03        .587   
  rs204938       4               AG vs AA           0.96 (0.83‐1.12)      0.48                               .63             0.97    0          .81    .922
  4              GG vs AA        0.97 (0.74‐1.28)   0.21                  .83                                4.11            27      .25        .044   
  4              AG + GG vs AA   0.97 (0.84‐1.13)   0.36                  .72                                1.76            0       .62        .685   
  4              GG vs AG + AA   0.92 (0.76‐1.12)   0.79                  .43                                4.20            28      .24        .046   
  8              G vs A          1.13 (1.00‐1.26)   2.03                  .04                                20.15           65      .005       .635   
  rs2168101      2               GT vs GG           0.54 (0.45‐0.66)      6.13                               \<.00001        0.25    0          .61    --
  2              TT vs GG        0.39 (0.25‐0.60)   4.17                  \<.00001                           1.56            36      .21        --     
  2              GT + TT vs GG   0.52 (0.43‐0.63)   6.84                  \<.00001                           0.01            0       .91        --     
  2              TT vs GT + GG   0.48 (0.31‐0.75)   3.21                  .001                               1.70            41      .19               
  3              G vs T          0.64 (0.55‐0.74)   5.96                  \<.00001                           4.54            56      .10        --     

John Wiley & Sons, Ltd

![Forest plot representing the association between the LMO1 rs110419 polymorphism and neuroblastoma susceptibility in allele genetic models (G vs A)](JCMM-24-1160-g002){#jcmm14836-fig-0002}

The rs4758051 variant markedly decreased the risk of NB in homozygous (OR = 0.76, 95%CI = 0.61‐0.96, *P* = .02, AA vs GG), dominant (OR = 0.68, 95%CI = 0.59‐0.78, *P* = .04, AG + GG vs AA) and allele (OR = 0.86, 95%CI = 0.75‐0.99, *P* = .03, A vs G) genetic models (Table [2](#jcmm14836-tbl-0002){ref-type="table"}, Figure [3](#jcmm14836-fig-0003){ref-type="fig"}). Similar findings were true for the rs10840002 variant, but only in the allele genetic model OR = 0.87, 95%CI = 0.79‐0.95, *P* = .003, G vs A; Table [2](#jcmm14836-tbl-0002){ref-type="table"}). In addition, the rs2168101 polymorphism was associated with decreased risk of NB susceptibility in heterozygous (OR = 0.54, 95%CI = 0.45‐0.66, *P* \< .00001, GT vs GG), homozygous (OR = 0.39, 95%CI = 0.25‐0.60, *P* \< .00001, TT vs GG), dominant (OR = 0.52, 95%CI = 0.43‐0.63, *P* \< .00001, GT + TT vs GG), recessive (OR = 0.48, 95%CI = 0.31‐0.75, *P* = .001, TT vs GT + GG) and allele (OR = 0.64, 95%CI = 0.55‐0.74, *P* \< .00001, G vs T) genetic models (Table [2](#jcmm14836-tbl-0002){ref-type="table"}). In contrast to the other polymorphisms evaluated, the results revealed that rs204938 marginally increased the risk of NB in the allele genetic model (OR = 1.13, 95%CI = 1.00‐1.26, *P* = .04, G vs A; Table [2](#jcmm14836-tbl-0002){ref-type="table"}).

![Forest plot representing the association between the LMO1 rs4758051 polymorphism and neuroblastoma susceptibility in allele genetic models (A vs G)](JCMM-24-1160-g003){#jcmm14836-fig-0003}

### 3.1.2. Heterogeneity and publication bias {#jcmm14836-sec-0009}

Between‐study heterogeneity across studies included into pooled analysis is displayed in Table [2](#jcmm14836-tbl-0002){ref-type="table"}. No evidence of heterogeneity was observed between studies for rs110419 and rs2168101 polymorphisms. For rs4758051; however, heterogeneity was identified in all codominant, dominant, recessive and allele genetic models (Table [2](#jcmm14836-tbl-0002){ref-type="table"}). Regarding rs10840002, no heterogeneity was observed in heterozygous, homozygous and dominant genetic models. No evidence of heterogeneity was found for rs204938 in heterozygous, homozygous, dominant and recessive genetic models (Table [2](#jcmm14836-tbl-0002){ref-type="table"}).

Begg\'s funnel plots and Egger\'s tests were performed to estimate the publication bias of the included literature. The Egger\'s tests revealed no existence of publication bias for all polymorphisms, except rs204938 in homozygous and recessive genetic models (Table [2](#jcmm14836-tbl-0002){ref-type="table"}, Figure [4](#jcmm14836-fig-0004){ref-type="fig"}).

![Begg\'s funnel plot for the association between the LMO1 rs110419 polymorphism and neuroblastoma risk (G vs A)](JCMM-24-1160-g004){#jcmm14836-fig-0004}

### 3.1.3. Sensitivity analysis {#jcmm14836-sec-0010}

Sensitivity analysis was conducted to assess the effects of individual studies on the stability of the pooled ORs. With sequential removal of individual study results from the analysis for rs110419, the pooled ORs remained significantly consistent in heterozygous, homozygous, recessive, dominant and allele genetic models (Figure [5](#jcmm14836-fig-0005){ref-type="fig"}). With regards to rs10840002, the ORs remained unchanged in heterozygous and allele genetic models. Lastly, the pooled ORs changed in all genetic models for rs204938 and rs4758051 polymorphisms.

![Sensitivity analyses of studies on the association of the LMO1 rs110419 polymorphism and neuroblastoma (G vs A)](JCMM-24-1160-g005){#jcmm14836-fig-0005}

4. DISCUSSION {#jcmm14836-sec-0011}
=============

Genetic susceptibility to NB has led to growing attention of the studies focused on genetic variations. To date, several reports on the potential association between LMO1 polymorphisms and NB development have been published, but the findings were inconsistent. Somehow surprisingly, none of the polymorphisms are in the coding region of the LMO1 gene. Therefore, they do not result in any amino acid change. They seem not to be related to splicing variants either and; therefore, the nature of their association with susceptibility to NB remains elusive. Three polymorphisms: rs110419, rs2168101 and rs204938 are located in the intron 1, while rs4758051 and rs1084000 are in the intergenic region, beyond the last, fourth exon of the LMO1 gene. Hence, the analysed polymorphisms most likely affect regulatory mechanisms within the LMO1 gene.

Our meta‐analysis, based on systematically collected studies, aimed to obtain an accurate summary of the estimates of the strength of association between specific LMO1 gene polymorphisms and NB susceptibility, and, to our best knowledge, is the first to do so. We found that rs110419, rs4758051, rs10840002 and rs2168101 polymorphisms were associated with reduced susceptibility to NB, while the rs204938 polymorphism increased the risk of the disease.

He et al[30](#jcmm14836-bib-0030){ref-type="ref"} reported that rs110419, rs10840002, rs4758051 and rs2168101 polymorphisms of the LMO1 gene were associated with a decreased risk of NB in an eastern Chinese subpopulation. In addition, the rs2168101 and rs3750952 polymorphisms were markedly associated with decreased NB susceptibility in children from North and South China.[28](#jcmm14836-bib-0028){ref-type="ref"} Similarly, the LMO1 rs110419 A \> G polymorphism was linked to a reduced NB risk in Southern Chinese children.[29](#jcmm14836-bib-0029){ref-type="ref"} A significant association between the rs204926 variant and NB susceptibility has been reported,[32](#jcmm14836-bib-0032){ref-type="ref"} and rs4758051 and rs10840002 polymorphisms were associated with decreased NB.[33](#jcmm14836-bib-0033){ref-type="ref"} Furthermore, a significant association between the rs110419 polymorphism and risk of NB was observed in an Italian population as well as European American children.[27](#jcmm14836-bib-0027){ref-type="ref"} Conversely, no significant associations between LMO1 polymorphisms and NB risk were observed in African Americans.[31](#jcmm14836-bib-0031){ref-type="ref"} While some studies indicate that frequently occurring polymorphisms at the LMO1 locus are strongly connected to susceptibility to developing NB.[14](#jcmm14836-bib-0014){ref-type="ref"} The observed differences in susceptibility, between populations, are likely due to the overall genetic background that modifies the LMO1 prone risk factors.

This meta‐analysis has a few limitations that should be considered. First, we have only included studies published in the English language. Second, there was significant heterogeneity among studies. There was also variation in study sample size, populations and ethnicity of participants, (please see Table [1](#jcmm14836-tbl-0001){ref-type="table"} for details). Third, our findings were obtained with a relatively limited sample size and consequently, our conclusions are preliminary in nature. Fourth, the assessments of gene‐gene and gene/environment interactions were not performed despite some data suggest so.

In conclusion, our meta‐analysis is the first to provide evidence of an association between specific genetic polymorphisms of the LMO1 gene and susceptibility to NB. Further validation by well‐designed studies performed by international multicenter programme (addressing diverse ethnic populations) is needed to conclusively confirm the impact of specific LMOI polymorphisms on NB susceptibility and development. Unfortunately, at present we lack sufficient number of studies (studied populations) to reliably perform such analyses. Nevertheless, the presented analysis offers interesting insight into the analysed polymorphisms, as outlined above.
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